SCHEMBL3015533

SCHEMBL3015533

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4cc(F)ccc4C)CC3)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
LMNA P02545 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
AR P10275 1/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 3/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
F2RL3 Q96RI0 1/20 0.35
ALDH1A1 P00352 4/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 2/20 0.35
POLB P06746 1/20 0.35
ADRB2 P07550 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CCR3 P51677 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009180 0.94 MAPT (0.42) MAPTLMNATDP1ARTHRB
SCHEMBL3008286 0.91 MAPT (0.41) MAPTLMNATDP1ARTHRB
SCHEMBL3021262 0.91 AR (0.40) MAPTLMNATDP1ARRECQL
SCHEMBL3006774 0.90 CTSS (0.42) MAPTLMNATDP1ARTHRB
SCHEMBL3014084 0.88 RAB9A (0.38) MAPTLMNATDP1ARRECQL
SCHEMBL3021620 0.88 MAPT (0.45) MAPTLMNATDP1ARRECQL
SCHEMBL3014447 0.88 ALDH1A1 (0.43) MAPTLMNATDP1THRBRECQL
SCHEMBL3019361 0.87 RAB9A (0.39) MAPTLMNATDP1RECQLHSD17B10
SCHEMBL3010103 0.87 MAPT (0.47) MAPTLMNATDP1RECQLHSD17B10
SCHEMBL3011422 0.87 AR (0.39) MAPTLMNATDP1ARTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TDP1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.